

Molecular Biochemical Aspects of Cancer

Undurti N. Das

Molecular Biochemical Aspects of Cancer

 Humana Press

Undurti N. Das
BioScience Research Centre and Department of Medicine
GVP Medical College and Hospital
Visakhapatnam, India
UND Life Sciences, Battle ground
WA, USA

ISBN 978-1-0716-0739-8 ISBN 978-1-0716-0741-1 (eBook)
<https://doi.org/10.1007/978-1-0716-0741-1>

© Springer Science+Business Media, LLC, part of Springer Nature 2020

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Humana imprint is published by the registered company Springer Science+Business Media, LLC, part of Springer Nature.

The registered company address is: 1 New York Plaza, New York, NY 10004, U.S.A.

To
My wife Lakshmi
Friend, philosopher, critic, supporter, and soul
and
for her understanding of my long hours at work.

Preface

Cancer is one of the leading causes of morbidity and mortality in both developing and developed countries. Despite many advances both in our understanding of its molecular biology and development of many newer therapeutics, it continues to be a major health issue. Tumor cells differ from normal cells in many aspects (including gene expressions, metabolism, behavior in terms of proliferation, and ability to metastasize, etc.) but the role of lipids in cancer has largely been ignored. The cell membrane (including nuclear membrane, mitochondrial membrane, etc.) lipid composition of tumor cells is different from normal, a fundamental property that has not been paid much attention. Lipids, especially polyunsaturated fatty acids (PUFAs) and their metabolites, both pro- and anti-inflammatory products, seem to play a critical role in the pathobiology of cancer. Tumor cells are deficient in the activity of desaturases that are essential for the formation of long-chain metabolites from dietary essential fatty acids: *cis*-linoleic acid (LA) and α -linolenic acid (ALA). As a result, tumor cells contain low quantities of γ -linolenic acid (GLA, 18: n-6), dihomog-LA (DGLA, 20:3 n-6), arachidonic acid (AA, 20:4 n-6) formed from LA and eicosapentaenoic acid (EPA, 20:5 n-3), and docosahexaenoic acid (DHA, 22:6 n-3) from ALA that can be referred to as *bioactive lipids* (which also include their metabolites). As a result, the tumor cell membrane is uniquely different from the normal especially in terms of expression of several receptors on its surface, the way messages are conveyed from the membrane to the DNA and *vice versa*, and its antigenicity including the expression of immune checkpoint proteins/receptors such as PD-1, PD-L1, and CTLA4. These altered properties of tumor cell may render it to escape the immune surveillance system and acquire unique properties in terms of its proliferation ability, metastasis, triggering angiogenesis to survive, and drug-resistance. Studies performed by us and several others showed that tumor cells have low rates of peroxidation and are exquisitely sensitive to the cytotoxic action of lipid peroxides compared to their normal counter parts. Furthermore, some of these *bioactive lipids* protect normal cells from the cytotoxic action of chemicals, chemotherapeutic drugs, cytokines, and radiation. This differential action of *bioactive lipids* on normal and tumor cells (protecting normal cells but produce apoptosis of tumor cells) could be exploited to develop them as potential drugs for cancer. These

bioactive lipids seem to regulate the proliferation and action of Treg and Teff cells; cytokines production and action; expression of PD-1, PD-L1, and CTLA4; macrophage function; immune response; and finally as potential mediators of the tumoricidal action of T cells, macrophages, and immune checkpoint inhibitors. They possess antimicrobial properties. These pleiotropic actions of *bioactive lipids* suggest that they are likely to be useful in several diseases. Our recent observation that drug-resistant Hodgkin's Lymphoma could be successfully treated by *bioactive lipids* when supplemented with chemotherapeutic drugs with substantial attenuation of side-effects of conventional anti-cancer drugs implies that they have the potential to be exploited as unconventional yet specific and selective anti-cancer molecules. The therapeutic potential of *bioactive lipids* is just being realized and it is only the beginning, and I foresee a bright future for lipid-based drugs for several diseases.

Visakhapatnam, India
Battle Ground, WA, USA

Undurti N. Das

Contents

1	Introduction to Genes, Oncogenes, and Anti-oncogenes	1
	Introduction.	1
	Retinoblastoma Gene	3
	Function and Properties of RB1	3
	Neurons	4
	Interaction of Retinoblastoma Protein with Several Other Receptors, Proteins, and Genes.	5
	p53.	6
	Functions of p53	6
	Factors Regulating p53	8
	p53 in Some Diseases	9
	Interaction(s) of p53 with Other Genes, Proteins, and Molecules	10
	p53 and Inflammation	10
	Phosphatase and Tensin Homolog (PTEN) in Cancer	12
	Clinical Significance of PTEN	12
	PTEN, Brain Function, and Autism	14
	Immune Checkpoint Inhibitors in Cancer.	20
	PD-L1 Inhibitors Include	21
	Bioactive Lipids and Immune Response in Cancer	22
	Prostaglandin E2 (PGE2) and Immune Checkpoint Inhibition.	24
	LXA4 Versus PGE2 in Cancer	24
	References.	29
2	Introduction to Free Radicals, Antioxidants, Lipid Peroxidation, and Their Effects on Cell Proliferation	41
	Introduction.	41
	Free Radicals.	43
	Formation of Free Radicals.	44
	Persistence and Stability of Free Radicals	44
	Diradicals	45
	Free Radical Reaction.	45

Combustion	45
Polymerization	46
Radicals Present in the Atmosphere	46
Biological Significance of Free Radicals	46
Identification and Diagnostic Techniques to Detect Free Radicals.	48
Nitric Oxide (NO).	48
Methods of Preparation of NO	49
Methods of Measurement of NO	50
Biological Functions/Significance of NO.	50
NO in Inflammation, Immune Response, and Cancer	53
NO Induces Apoptosis of Cancer Cells	54
Oxidative Stress in Cancer Initiation and Progression Including Apoptosis and Necrosis	55
References.	57
3 Immune System, Inflammation, and Essential Fatty Acids and Their Metabolites in Cancer.	67
Introduction to the Immune System	67
Innate Immune System	68
Inflammation.	69
NK Cells	70
Adaptive Immune System or Acquired Immune System	71
Lymphocytes	71
Killer T Cells.	72
Helper T Cells.	73
$\gamma\delta$ T Cells	74
T_H1/T_H2 Model for Helper T Cells	75
Suppressor T Cells	75
T_{reg} Cells and Autoimmune Diseases	78
Methods to Analyze and Monitor T_{reg} Cells	79
B Lymphocytes	80
Toxic Shock Syndrome.	81
Superantigens and the Immune System	81
Immunological Aspects of Cancer	82
Immunosurveillance and Immunoediting	83
PD-1 (Programmed Cell Death Protein 1)	88
T_H17 –Treg Cell Balance	89
IL-17, Synaptic Plasticity, and Memory	91
Cancer and Autoimmune Diseases Are Two Sides of the Same Coin.	94
IL-17 and Fibrosis.	97
Macrophages in Tissue Repair (Regeneration) and Fibrosis	98
PUFAs, Ion Channels, Cell Proliferation, or Apoptosis	101

Prostanoids in Inflammation	106
PGE2 and PD-1 and CTL (Cytotoxic T Lymphocyte) Function	107
Tumor Cells and Lipid Peroxidation.	109
Tumor Cells Are Relatively Rich in Vitamin E.	109
SOD and Tumor Cells.	113
Tumor Necrosis Factor (TNF) and PUFAs	115
Anti-cancer Drugs, ROS, and SOD	116
Free Radicals, Lipid Peroxides, p53, Caspases, and Apoptosis	117
Oxidant Stress, Bcl-2, and Apoptosis	118
Connecting the Plasma Membrane to the Nucleus	120
PUFAs Enhance Lipid Peroxidation and Inhibit Cell Proliferation	121
PUFA-Activated Macrophages Possess Tumoricidal Action	122
PUFAs Are Involved in Various Mitochondrial Processes	123
PUFAs Augment Cytotoxic Action of Anti-cancer Drugs and Reverse Drug Resistance	124
Differential Metabolism of PUFAs by Normal and Tumor Cells	125
PUFAs and Telomerase Activity	129
PUFAs Can Modulate G-Protein-Mediated Signals	130
Differential Action Due to Differences in the Metabolism of PUFAs Makes All the Difference	130
References.	131
4 PUFAs and Their Metabolites in Carcinogenesis.	159
Introduction.	159
Genomic Instability and Cancer	161
Bioactive Lipids and Mutagenesis/Carcinogenesis.	163
PGE2, LXA4, and Treg and Teff Cells and Inflammation	163
Bioactive Lipids in Mutagenesis and Carcinogenesis.	169
References.	175
5 Molecular Mechanism of Anti-cancer Action of PUFAs with Particular Reference to GLA in Glioma	181
Introduction.	181
Metabolism of Essential Fatty Acids (EFAs)	182
Anti-cancer Action of PUFAs	184
ROS and Lipid Peroxides as Mediators of the Anti-cancer Action of PUFAs (Bioactive Lipids: BAL).	187
PUFAs and Immune System in Cancer.	188
PUFAs (Especially GLA) Have Anti-angiogenic Action	193
Mechanism of Action of PUFAs/GLA on Tumor Cells	194
GLA for Glioma Management	197
Examples.	198
Methods of Administration	198
References.	200

6 Bioactive Lipid (BAL)-Based Therapeutic Approach to Cancer That Enhances Antitumor Action and Ameliorates Cytokine Release Syndrome of Immune Checkpoint Inhibitors.	207
Introduction.	208
Immune Checkpoint Inhibitors.	208
CTLA-4.	210
Indoleamine-Pyrrole 2,3-Dioxygenase (IDO or INDO).	212
Immune Checkpoint Inhibitors in Cancer.	214
Bioactive Lipids Have Tumor Growth Inhibitory and Tumorcidal Action.	216
PUFAs Enhance the Tumorcidal Action of TILs and/or CAR T-Cell Therapy.	217
PD-1, PD-L1, CTLA-4, IDO, and PUFAs	221
Conclusions and Therapeutic Implications.	223
References.	225
7 A New Therapeutic Strategy to Treat Cancer Based on Bioactive Lipids (BAL)	237
Introduction.	237
Bioactive Lipids for Cancer	238
Intratumoral Delivery by Injection/Infusion.	238
Lithium-GLA-Iodized Solution Complex (LGIOC) for Intra-arterial Injection/Infusion.	238
BAL Conjugated to Growth Factors (EGF/VEGF)/Antigrowth Factor(s) Antibodies	239
Conjugation of BAL with Angiostatin and Endostatin	239
TNF- α /IL-6-BAL Complex	239
PUFAs Anti-cancer Drug Complexes	240
PUFA-Based Nanoparticles in Combination with Growth Factors/Monoclonal Antibodies to Growth Factors/TNF- α /Angiostatin/Endostatin/Anti-cancer Drugs.	240
PUFAs Delivered Using Biodegradable Membranes	240
BAL-CAR T-Cell Immune Checkpoint Inhibitors.	240
Conclusion and Future Perspective.	241
References.	243
Index.	245

About the Author



Undurti N. Das is an MD in Internal Medicine from Osmania Medical College, Hyderabad, India; a Fellow of the National Academy of Medical Sciences, India; and Shanti Swaroop Bhatnagar prize awardee. Apart from clinical work, he is researching the role of polyunsaturated fatty acids, cytokines, nitric oxide, free radicals, and anti-oxidants in cancer, inflammation, metabolic syndrome, schizophrenia, autism, and tropical diseases. His current interests include cancer, molecular biological aspects of diabetes mellitus, hypertension, cardiovascular diseases, and metabolic syndrome. Dr Das was formerly scientist at Efamol Research Institute, Kentville, Canada; Professor of Medicine at Nizam's Institute of Medical Sciences, Hyderabad, India; and Research Professor of Surgery and Nutrition at SUNY (State University of New York) Upstate Medical University, Syracuse, USA. At present, he is the Chairman and Research Director of UND Life Sciences LLC, Battle Ground, WA, USA, and Chairman and Professor of Department of Medicine, GVP Hospital and Medical College, Visakhapatnam, India, and serves as a consultant to both Indian and US-based biotech and pharmaceutical companies. Dr Das is the Founding *Editor* of the international journal: *Lipids in Health and Disease* and serves on the editorial board of another 10 international journals. Dr Das has authored more than 500 international publications, written 4 books, and has been awarded 6 US patents. He is now developing lipid-based drugs for cancer, diabetes mellitus, and sepsis.